Tacrolimus and Retrognathia - a phase IV clinical study of FDA data

Summary:

Retrognathia is reported as a side effect among people who take Tacrolimus (tacrolimus), especially for people who are female, 30-39 old, also take Fluvastatin, and have Foetal exposure during pregnancy.

The phase IV clinical study analyzes which people have Retrognathia when taking Tacrolimus. It is created by eHealthMe based on reports of 115,828 people who have side effects when taking Tacrolimus from the FDA, and is updated regularly.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,161 Tacrolimus users. Check the latest studies of Tacrolimus.

What is Retrognathia?

Retrognathia (a condition in which either or both jaws recede with respect to the frontal plane of the forehead) is found to be associated with 35 drugs and 102 conditions by eHealthMe. Check the latest studies of Retrognathia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

115,828 people reported to have side effects when taking Tacrolimus.
Among them, 20 people (0.02%) have Retrognathia.

Among these 20 people:

What is the gender of people who have Retrognathia when taking Tacrolimus? *

female: 83.33 %
male: 16.67 %

What is the age of people who have Retrognathia when taking Tacrolimus? *

What are other drugs people take besides Tacrolimus? *

What are other side effects people have besides Retrognathia? *

Dysmorphism (difference of body structure that is suggestive of a congenital disorder): 18 people, 90.00%
Limb Reduction Defect (a birth defect in which all or some of the limbs of a foetus do not completely form while in utero): 12 people, 60.00%
Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 12 people, 60.00%
Aplasia (defective development or congenital absence of an organ or tissue): 11 people, 55.00%
Premature Baby: 11 people, 55.00%
Neck Deformity (neck malformation): 11 people, 55.00%
Limb Hypoplasia Congenital (incomplete developed limb): 10 people, 50.00%
Iris Hypopigmentation (unusual lack of skin colour of iris): 3 people, 15.00%
Ureteric Dilatation: 3 people, 15.00%
Hypertelorism Of Orbit (abnormally increased distance between two organs or bodily parts, usually referring to an increased distance between the orbits (eyes)--orbital hypertelorism): 3 people, 15.00%

What are the existing conditions these people have? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 9 people, 45.00%
Nephrotic Syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema): 4 people, 20.00%
High Blood Cholesterol: 4 people, 20.00%
Glomerulonephritis (a group of conditions that affect parts of the kidneys called glomeruli): 4 people, 20.00%
Idiopathic Thrombocytopenic Purpura (Itp) (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 3 people, 15.00%
High Blood Pressure: 3 people, 15.00%
Drug Exposure During Pregnancy: 2 people, 10.00%
Breast Cancer: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tacrolimus and have Retrognathia?

- Check whether Retrognathia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tacrolimus:

Tacrolimus (116,161 reports)

Retrognathia treatments and more:

Retrognathia (404 reports)

Browse all side effects of Tacrolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Retrognathia:

Retrognathia (35 drugs)

Browse all the conditions that are associated with Retrognathia:

Retrognathia (102 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Tacrolimus) and Tacrolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.